Formulation patents and dermatology and obviousness

1Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent law, recent court cases concerning obviousness and formulation patents were examined and discussed below. Courts have ruled that patent claims are obvious when features of the claimed formulation are found in the prior art, even if the features or characteristics of the formulation are not explicitly disclosed in the prior art. However, patentees have successfully overcome obviousness challenges where there were unexpected results or properties and/or the prior art taught away from the claimed invention. © 2011 by the authors; licensee MDPI, Basel, Switzerland.

Author supplied keywords

Cite

CITATION STYLE

APA

Mei, D. F., Liu, J., & Davitz, M. A. (2011). Formulation patents and dermatology and obviousness. Pharmaceutics, 3(4), 914–922. https://doi.org/10.3390/pharmaceutics3040914

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free